GE's Clarient Purchase Heightens Company's Focus on Tests for Cancer Drug Personalization | GenomeWeb

Originally published Oct. 26.

By Turna Ray

Continuing to aggrandize its presence in the personalized medicine space, GE Healthcare announced plans last week to scoop up Clarient for around $580 million.

The acquisition gives GE access to an array of molecular tests in oncology, a clinical laboratory for providing diagnostic services, and markers that can lead to the development of companion diagnostics for therapies treating leukemia, as well as breast, prostate, lung, and colon cancers.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Pacific Biosciences is hosting a competition in which researchers are vying to win free sequencing for an organism with the most interesting genome.

An opinion piece appearing in Newsday likens familial DNA searches to stop-and-frisk policies.

The San people of Africa have drawn up a code of conduct for researchers, according to the Conversation.

In Nature this week: genotypes linked to hip osteoarthritis, and more.